Navigation Links
Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S.
Date:10/17/2011

ence at 30 minutes (SPID30). More than 500 patients evaluated in the clinical trial program (which included three phase III clinical trials) contributed to the understanding of the tolerability and safety profile of Lazanda. The most common adverse events associated with Lazanda were consistent with opioid treatment and included vomiting, nausea, pyrexia (fever), and constipation.IMPORTANT SAFETY INFORMATION WARNINGS: POTENTIAL FOR ABUSE and IMPORTANCE OF PROPER PATIENT SELECTIONLazanda® contains fentanyl, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. Lazanda can be abused in a manner similar to other opioid agonists, legal or illicit. Consider the potential for abuse when prescribing or dispensing Lazanda in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion. Schedule II opioid substances, which include morphine, oxycodone, hydromorphone, oxymorphone, and methadone, have the highest potential for abuse and risk of fatal overdose due to respiratory depression. Serious adverse events, including deaths, in patients treated with other oral transmucosal fentanyl products have been reported.  Deaths occurred as a result of improper patient selection (e.g., use in opioid non-tolerant patients) and/or improper dosing. The substitution of Lazanda for any other fentanyl product may result in fatal overdose.Lazanda is indicated only for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking at least 60 mg of oral morphine/day, 25 mcg of transdermal fentanyl/hour, 30 mg of oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for one week or longer. Lazanda is
'/>"/>

SOURCE Archimedes Pharma Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Archimedes Pharma Announces Publication of Long-Term Safety and Tolerability Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in the Journal of Opioid Management
2. Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain
3. Archimedes Pharma Receives CHMP Positive Opinion for PecFent(R) for the Treatment of Breakthrough Cancer Pain
4. Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
5. Novo Nordisk A/S: PharmaVitae Profile
6. Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011
7. Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES
8. Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors
9. Access Pharmaceuticals Updates MuGard Website with New Video Featuring Clinical Feedback and Manufacturing Footage
10. CVS/pharmacy Ready to Provide Assistance During Medicare Part D Annual Enrollment Period
11. ShangPharma Corporation Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Research and Development Trend Forecast of Pharmaceutical ... offering. Research and Development Trend Forecast ... , 2014-2018 mainly analyzes China,s ... status, supply & demand, competition landscape, and business performance ...
(Date:8/29/2014)... , Aug. 29, 2014   Vittamed Corporation , ... announced today that T. (Teo) Forcht Dagi ... the company,s Board of Directors. " Teo ... career in neurosurgery, medical innovation and venture capital," said ... extremely delighted to add his clinical, strategic, and entrepreneurial expertise ...
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely ... a generation ago are returning. Measles was declared eliminated ... in 2014 as of August 15—the highest incidence in ... public health department declared whooping cough a problem of ... are getting sick and dying from these preventable diseases—in ...
Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... 19, 2007 - Abraxis BioScience,Inc. (NASDAQ:ABBI), ... from two pre-clinical studies that,provide evidence ... combining nab-paclitaxel (ABRAXANE(R) for Injectable,Suspension (paclitaxel ... VEGF inhibitor drugs like,bevacizumab (Avastin(R)) at ...
... WIRE)--Apr 19, 2007 - Abraxis BioScience,Inc. ... first-time data from a pre-clinical study,evaluating ... nab-rapamycin,(ABI-009), an albumin-bound mTOR kinase inhibitor, ... Research (AACR) Annual Meeting held,April 14-18, ...
Cached Medicine Technology:Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 2Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 3Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 4
(Date:8/30/2014)... HealthDay Reporter FRIDAY, Aug. ... operated on for broken bones or other orthopedic trauma shops ... Less-educated patients and patients who had used narcotic ... shoppers," said study lead author Dr. Brent Morris, a shoulder ... study suggests that doctors aren,t talking to one another about ...
(Date:8/30/2014)... Market Research Report on Global and ... and in-depth market survey on Global and Chinese ... basic information of Lab Oven including its classification, ... global and China’s top manufacturers of Lab Oven ... market share etc. , The report further analyzes ...
(Date:8/30/2014)... 30, 2014 "I had a handicapped friend ... crutches," said an inventor from Wetumpka, Ala. "In order to ... of the shore, I came up with a way for ... created a prototype for the patent-pending Deezers to allow crutches ... individual to use crutches, walkers, or canes at the beach. ...
(Date:8/30/2014)... 2014 Top10BestSEOHosting.com is a well-known ... announced that HostGator.com http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts is the ... Also, they has announced that Bluehost and Arvixe ... Hostgator, one of the Top 10 Web Hosting ... Windows hosting, and it offers rich features and ...
(Date:8/30/2014)... August 30, 2014 Ms. Meriwether’s striking beauty ... She certainly has an impressive resume to boost. Nana ... in 2012. However, she’s also a two time All ... Nana trained for the 2008 Olympics and played professional ... website, “This six-foot beauty from Potomac, Maryland is a two-time, ...
Breaking Medicine News(10 mins):Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Top10BestSEOHosting.com: HostGator.com Is The Best Windows Hosting Supplier 2Health News:NJ Top Dentists Announces Cover Model for the Healthy Living: Top Dentists Issue 2
... www.deo.ucsf.edu , has been launched by the University of California, ... successful American Diabetes Association (ADA) accredited teaching program curriculum created by ... the past 30 years. , ... SAN FRANCISCO ...
... Successful And Effective Campaign Could Help Prevent,Another Blood Crisis, ... Just Six Coaches, Orlando Has 35!!!, NEW YORK, ... a dangerous blood emergency, New York City Councilman Eric ... and,Investigation, and representatives of New York Blood Center called ...
... Findley Davies announced today,the hiring of Tod ... Charlotte,Office effective August 1, 2008. He will be ... Benefits Practice in North Carolina and,surrounding areas. Tod ... as a Health and Welfare consultant for a ...
... new report on severe sporting injuries among high school ... a larger proportion of all such injuries than previously ... of North Carolina at Chapel Hill-based National Center for ... for 65.1 percent of all catastrophic sports injuries among ...
... Aug. 11 STAAR Surgical,Company (Nasdaq: STAA ... invasive ophthalmic products, announced today that it will,present ... Financial Equity,Conference which will be held Monday, August ... Lake Las Vegas Resort, Nevada. Barry G. Caldwell,President ...
... Consumables Revenue Up 15% Year over Year ... Gross Profit Margin of 77%, HAYWARD, ... non-invasive tissue tightening in the aesthetic,industry, today reported its financial results for ... of 2008 totaled $17.9 million, an,increase of 2% from $17.5 million for ...
Cached Medicine News:Health News: 80 Million Americans Can Benefit from New Diabetes Resource : Free Educational Website Created by UCSF Diabetes Teaching Center Goes Live 2Health News:Gioia & New York Blood Center Call for City Aid in Expansion of Mobile Blood Donor Coach Program 2Health News:Gioia & New York Blood Center Call for City Aid in Expansion of Mobile Blood Donor Coach Program 3Health News:UNC study: Two-thirds of severe sports injuries to female students due to cheerleading 2Health News:STAAR Surgical to Present at the Noble Financial Equity Conference 2Health News:Thermage Announces Second Quarter 2008 Financial Results 2Health News:Thermage Announces Second Quarter 2008 Financial Results 3Health News:Thermage Announces Second Quarter 2008 Financial Results 4Health News:Thermage Announces Second Quarter 2008 Financial Results 5Health News:Thermage Announces Second Quarter 2008 Financial Results 6Health News:Thermage Announces Second Quarter 2008 Financial Results 7Health News:Thermage Announces Second Quarter 2008 Financial Results 8Health News:Thermage Announces Second Quarter 2008 Financial Results 9
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: